A multicenter, open-label, sequential study comparingpreferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease
References (9)
- et al.
“Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975) - et al.
Drug adherence in Parkinson's disease
Mov Disord
(2004) - et al.
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panelstudy of chronic disease
Health Qual Life Outcomes
(2004) - et al.
Quality of life and new antipsychotics in schizophrenia. Are patients better off?
Int J Soc Psychiatry
(1999)
Cited by (39)
Should “on-demand” treatments for Parkinson's disease OFF episodes be used earlier?
2022, Clinical Parkinsonism and Related DisordersChallenges and innovations of drug delivery in older age
2018, Advanced Drug Delivery ReviewsCitation Excerpt :The main advantages with ODTs are ease of handling, convenient to use, self-medication, rapid onset of action and enhance bioavailability due to pre-gastric absorption and most importantly higher acceptability and adherence [108–110]. Older patients suffering from dysphagia, nausea, vomiting, migraine, depression, schizophrenia and Parkinson diseases show a better adherence for ODTs compared with the conventional dosage forms [111–114]. A key limitation in using ODTs in the elderly is the reduction in saliva production with ageing [115], which is likely to impact on ODT disintegration and drug absorption.
Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations
2018, International Journal of PharmaceuticsPatients’ appropriateness, acceptability, usability and preferences for pharmaceutical preparations: Results from a literature review on clinical evidence
2017, International Journal of PharmaceuticsCitation Excerpt :In the other studies, conventional tablets were also used as comparator. Patients with neurological pathologies such as Parkinson's disease, schizophrenia or mood disorders showed preference for orodispersible tablets (Bitter et al., 2010; Nausieda et al., 2005; Sajatovic et al., 2013). Liquid-dispersible tablets were more accepted in dysphagic parkinsonian patients (Bayer et al., 1988), patients with breast cancer receiving highly emetogenic chemotherapy showed preference for a film formulation of dexamethasone (Nishigaki et al., 2012) and hemodialysis patients showed preference for a gelcap formulation (Kaplan et al., 2002).
Novel methods of drug administration for the treatment and care of older patients
2016, International Journal of PharmaceuticsCitation Excerpt :A number of ODTs have been developed for the treatment of conditions that are common in the older population such as pain, depression, Parkinson's disease and Alzheimer's disease (Slavkova and Breitkreutz, 2015), indicating that there is already a considerable body of evidence supporting patient acceptability of such a dosage form and the potential for improvements in adherence. Patient preference for an ODT compared to a conventional oral tablet or capsule has been demonstrated in cases of dysphagia (Carnaby-Mann and Crary, 2005), depression (Wade et al., 2012) and Parkinson's disease (Nausieda et al., 2005), for example. Despite the progression to market, with a number of products already available and used in older people, for example, Aricept® ODT (donepezil) and Parcopa® (carbidopa/levodopa), there remain some aspects of ODTs that may still be improved upon.